Gilead Sciences (GILD) : Keystone Financial Planning added new position in Gilead Sciences during the most recent quarter end. The investment management firm now holds 4,582 shares of Gilead Sciences which is valued at $338,243 , the company said in a statement filed on Oct 12, 2016 with the SEC.Gilead Sciences makes up approximately 0.23% of Keystone Financial Planning’s portfolio.
Other Hedge Funds, Including , Capstone Asset Management Co boosted its stake in GILD in the latest quarter, The investment management firm added 70,492 additional shares and now holds a total of 194,171 shares of Gilead Sciences which is valued at $14,333,703. Gilead Sciences makes up approx 0.42% of Capstone Asset Management Co’s portfolio. Community Trust Investment Co sold out all of its stake in GILD during the most recent quarter. The investment firm sold 125,451 shares of GILD which is valued $9,470,296.Founders Capital Management reduced its stake in GILD by selling 1,850 shares or 9.29% in the most recent quarter. The Hedge Fund company now holds 18,066 shares of GILD which is valued at $1,363,802. Gilead Sciences makes up approx 0.77% of Founders Capital Management’s portfolio. Stokes Hubbell Capital Management sold out all of its stake in GILD during the most recent quarter. The investment firm sold 2,706 shares of GILD which is valued $203,599.First American Trust Fsb reduced its stake in GILD by selling 27,156 shares or 89.24% in the most recent quarter. The Hedge Fund company now holds 3,276 shares of GILD which is valued at $254,119. Gilead Sciences makes up approx 0.08% of First American Trust Fsb’s portfolio.
Gilead Sciences closed down -1.67 points or -2.21% at $73.82 with 1,19,09,999 shares getting traded on Tuesday. Post opening the session at $75.14, the shares hit an intraday low of $73.56 and an intraday high of $75.28 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.
Many Wall Street Analysts have commented on Gilead Sciences. Shares were Reiterated by RBC Capital Mkts on Oct 3, 2016 to “Outperform” and Lowered the Price Target to $ 95 from a previous price target of $105 .Shares were Downgraded by Leerink Partners on Sep 27, 2016 to ” Mkt Perform” and Lowered the Price Target to $ 94 from a previous price target of $112 .Berenberg Initiated Gilead Sciences on Sep 12, 2016 to “Buy”, Price Target of the shares are set at $112.
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.